{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-105928","form_type":"8-K","ticker":"ACXP","cik":"0001736243","company_name":"Acurx Pharmaceuticals, Inc.","filed_at":"2023-10-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.261566+00:00","generated_at":"2026-06-10T06:25:51.100961+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Acurx discontinues Phase 2b ibezapolstat trial early on high cure rates, no safety concerns; Phase 3 accelerated","bullets":["Phase 2b discontinued after blinded data showed high clinical cure rates for ibezapolstat and vancomycin, with no emerging safety concerns.","Company expects to advance ibezapolstat to Phase 3 more expeditiously; topline efficacy results to be reported promptly.","Ibezapolstat is first-in-class, FDA QIDP/Fast-Track-designated antibiotic for C. difficile infection, potentially first new antibiotic class in 30+ years.","Decision also influenced by site maintenance costs and slow enrollment due to COVID-19; Independent Data Monitoring Committee will not perform interim analysis."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-105928","json":"https://secwatch.observer/filing/0001104659-23-105928.json","markdown":"https://secwatch.observer/filing/0001104659-23-105928.md","text":"https://secwatch.observer/filing/0001104659-23-105928.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1736243/000110465923105928/0001104659-23-105928-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1736243/000110465923105928/tm2327257d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T06:25:51.100961+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}